NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Medical Devices · USD

Perspective Therapeutics, Inc. (CATX) Stock Analysis

Perspective Therapeutics, Inc. (CATX) is a Medical Devices stock listed on NYSE American and quoted in US Dollar.

CATX

$3.13

+$0.01 (+0.32%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CATX with… →

CATX Key Statistics

As of Sep 4, 2026
Trading
Open
$3.07
Previous Close
$3.12
Day's Range
3.03–3.18
52-Week Range
1.96–6.16
Volume
1.37M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$357.29M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
873.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.33
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$103.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
114.15M
1-Year Return
−11.58%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
1.59M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CATX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.82%
2025−13.79%
2024−20.25%
2023+60.00%
2022−35.90%
2021−13.33%
2020−27.42%
2019+106.67%
2018−25.00%
2017−31.03%
2016 (partial year)−23.68%

As of September 4, 2026.

CATX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$103.12M—
2024$0.00−$79.28M—
2023$0.00−$46.51M—
2022$10.80M−$7.27M−67.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$113.56M−$103.12M—
2024$0.00—−$66.80M−$79.28M—
2023$0.00—−$40.94M−$46.51M—
2022$10.80M$4.62M−$7.39M−$7.27M−67.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CATX Valuation vs Medical Devices Median

Median of 151 stocks
MetricCATXMedical Devices medianvs median
P/S ratio873.582.98293.5x the median
Profit margin0.00%−1.69%1.7 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Perspective Therapeutics, Inc. (CATX) at $357.29M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 163 employees.

Over the past 52 weeks the price has ranged from $1.96 to $6.16. The most recent close on file for CATX is $3.13, dated September 4, 2026. That is +$0.01 (+0.32%) against the previous close. The latest close sits 59.69% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $103.12M. Profit margin runs at 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are −1.33.

Across the 4 fiscal years on file, revenue moves from $10.80M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 873.58. On price-to-sales that is 293.5 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.8. Daily returns over the trailing 10 years annualize to a volatility of 113.86%. The trailing one-year price return is −11.58%. Across 10 years the annualized return works out at −7.99%.

Growth & Income

The record shows no dividend for CATX.

The strongest complete calendar year on file is 2019 at +106.67%; the weakest is 2022 at −35.90%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +13.82% year to date.

Peer Comparison

Perspective Therapeutics, Inc. (CATX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Perspective Therapeutics, Inc. CATX $357.29M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Perspective Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Visit website →